XPR – Lifestyle Demo
Author:
Biovica International
Biovica International AB – Q3 Interim Report Nov 2025-Jan2026
March 18, 2026
New AACR Data Expand Evidence for TKa In Immunotherapy-Treated Patients and CDK Inhibitor Dose Optimization
March 18, 2026
Nomination Committee for Biovica International AB for the 2026 Annual General Meeting
March 9, 2026
Biovica Announces Planned CEO Succession; Anders Rylander to Step Down During 2026
March 5, 2026